المؤلفون: Osama Al-Dalahmah, Michael G. Argenziano, Adithya Kannan, Aayushi Mahajan, Julia Furnari, Fahad Paryani, Deborah Boyett, Akshay Save, Nelson Humala, Fatima Khan, Juncheng Li, Hong Lu, Yu Sun, John F. Tuddenham, Alexander R. Goldberg, Athanassios Dovas, Matei A. Banu, Tejaswi Sudhakar, Erin Bush, Andrew B. Lassman, Guy M. McKhann, Brian J. A. Gill, Brett Youngerman, Michael B. Sisti, Jeffrey N. Bruce, Peter A. Sims, Vilas Menon, Peter Canoll

المصدر: Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)

مصطلحات موضوعية: Science

الوصف: Abstract Glioblastoma (GBM) diffusely infiltrates the brain and intermingles with non-neoplastic brain cells, including astrocytes, neurons and microglia/myeloid cells. This complex mixture of cell types forms the biological context for therapeutic response and tumor recurrence. We used single-nucleus RNA sequencing and spatial transcriptomics to determine the cellular composition and transcriptional states in primary and recurrent glioma and identified three compositional ‘tissue-states’ defined by cohabitation patterns between specific subpopulations of neoplastic and non-neoplastic brain cells. These tissue-states correlated with radiographic, histopathologic, and prognostic features and were enriched in distinct metabolic pathways. Fatty acid biosynthesis was enriched in the tissue-state defined by the cohabitation of astrocyte-like/mesenchymal glioma cells, reactive astrocytes, and macrophages, and was associated with recurrent GBM and shorter survival. Treating acute slices of GBM with a fatty acid synthesis inhibitor depleted the transcriptional signature of this pernicious tissue-state. These findings point to therapies that target interdependencies in the GBM microenvironment.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2041-1723Test

الوصول الحر: https://doaj.org/article/84706af8be0f4cffa61c89d018e75e54Test

المؤلفون: Michael G. Argenziano, Julia L. Furnari, Michael L. Miller, Yu Sun, Matei A. Banu, Justin A. Neira, Matija Snuderl, Jeffrey N. Bruce, Mary Welch, Paul McCormick, Peter Canoll

المصدر: Acta Neuropathologica Communications, Vol 10, Iss 1, Pp 1-7 (2022)

مصطلحات موضوعية: H3 K27M, Intramedullary tumor, Low grade glioma, PTPN11, MAPK signaling pathway, Neurology. Diseases of the nervous system, RC346-429

الوصف: Abstract We present the case of a 41-year-old man who developed worsening mid-thoracic back pain and imaging revealed a well-circumscribed intramedullary tumor in the thoracic spinal cord. Subtotal resection was performed, and histopathological analysis showed a cytologically bland, minimally proliferative glial neoplasm. Sequencing revealed H3 K27M and an activating PTPN11 mutation. Serial imaging revealed slow tumor regrowth over a three year period which prompted a second resection. The recurrent tumor displayed a similar low grade-appearing histology and harbored the same H3 K27M and PTPN11 mutations as the primary. While the prognostic importance of isolated H3 K27M in spinal gliomas is well-known, the combination of these two mutations in spinal low grade glioma has not been previously reported. Importantly, PTPN11 is a component of the MAPK signaling pathway. Thus, as building evidence shows that low grade-appearing gliomas harboring H3 K27M mutations along with BRAF or FGFR1 mutations have a relatively more favorable course compared to isolated H3 K27M-mutant midline gliomas, the present case provides new evidence for the prognostic importance of activating mutations in other components of the MAPK signaling pathway. This case further highlights the importance of clinico-radio-pathologic correlation when incorporating evolving genetic data into the integrated diagnosis of rare neuroepithelial tumors.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2051-5960Test

الوصول الحر: https://doaj.org/article/0c25799048174155b51d0a19071a0280Test

المؤلفون: M. C. Fargnoli, M. Esposito, S. Ferrucci, G. Girolomoni, A. Offidani, A. Patrizi, K. Peris, A. Costanzo, G. Malara, G. Pellacani, M. Romanelli, P. Amerio, A. Cristaudo, M. L. Flori, A. Motolese, P. Betto, C. Patruno, P. Pigatto, C. Peccianti, G. Stinco, I. Zalaudek, L. Bianchi, V. Boccaletti, S. P. Cannavo, F. Cusano, S. Lembo, R. Mozzillo, R. Gallo, C. Potenza, F. Rongioletti, R. Tiberio, T. Grieco, G. Micali, S. Persechino, M. Pettinato, S. Pucci, L. Stingeni, C. Caruso, G. Argenziano

المصدر: Journal of Dermatological Treatment, Vol 33, Iss 2, Pp 1146-1149 (2022)

مصطلحات موضوعية: Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/2cf0b3533d464158beffd88a41098edcTest

المؤلفون: A Chiricozzi, SM Ferrucci, L Di Nardo, N Gori, A Balato, M Ortoncelli, M Maurelli, M Galluzzo, M Munera Campos, T Seremet, G Caldarola, C De Simone, E Ippoliti, T Torres, S Gkalpakiotis, C Conrad, JM Carrascosa, Luca Bianchi, G Argenziano, S Ribero, G Girolomoni, AV Marzano, K Peris

المساهمون: Chiricozzi, A, Ferrucci, Sm, Di Nardo, L, Gori, N, Balato, A, Ortoncelli, M, Maurelli, M, Galluzzo, M, Munera Campos, M, Seremet, T, Caldarola, G, De Simone, C, Ippoliti, E, Torres, T, Gkalpakiotis, S, Conrad, C, Carrascosa, Jm, Bianchi, Luca, Argenziano, G, Ribero, S, Girolomoni, G, Marzano, Av, Peris, K

مصطلحات موضوعية: Atopic dermatiti, eczema tralokinumab, IL-13 inhibitor, Treatment goals

الوصف: Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. Research design and methods: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. Results: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumabtreated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. Conclusions: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.

العلاقة: firstpage:1307; lastpage:1315; numberofpages:9; journal:EXPERT OPINION ON BIOLOGICAL THERAPY; https://hdl.handle.net/11562/1117066Test

الإتاحة: https://doi.org/10.1080/14712598.2023.2292627Test
https://hdl.handle.net/11562/1117066Test

المؤلفون: M. C. Fargnoli, M. Esposito, S. Ferrucci, G. Girolomoni, A. Offidani, A. Patrizi, K. Peris, A. Costanzo, G. Malara, G. Pellacani, M. Romanelli, P. Amerio, A. Cristaudo, M. L. Flori, A. Motolese, P. Betto, C. Patruno, P. Pigatto, R. Sirna, G. Stinco, I. Zalaudek, L. Bianchi, V. Boccaletti, S. P. Cannavò, F. Cusano, S. Lembo, R. Mozzillo, R. Gallo, C. Potenza, F. Rongioletti, R. Tiberio, T. Grieco, G. Micali, S. Persechino, M. Pettinato, S. Pucci, E. Savi, L. Stingeni, A. Romano, G. Argenziano, On behalf of the Dupilumab Italian National Access Program (Dup-INAP group)

المصدر: Journal of Dermatological Treatment, Vol 32, Iss 5, Pp 507-513 (2021)

مصطلحات موضوعية: atopic dermatitis, dupilumab, real-life, Dermatology, RL1-803

الوصف: Background Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/ecb70d51478d43e187fc250c22a1b43aTest

المؤلفون: Michael T Yin, Ruijun Chen, George Hripcsak, Magdalena E Sobieszczyk, Sherif M Shoucri, Lawrence Purpura, Clare DeLaurentis, Matthew A Adan, Deborah A Theodore, Alexandria Lauren Irace, Shelief Y Robbins-Juarez, Apurva M Khedagi, Daniel Letchford, Amro A Harb, Lillian M Zerihun, Kate E Lee, Karen Gambina, Max C Lauring, Noah Chen, Colin P Sperring, Sanket S Mehta, Ellen L Myers, Hueyjong Shih, Michael G Argenziano, Samuel L Bruce, Cody L Slater, Jonathan R Tiao, Karthik Natarajan, Delivette Castor, Jason E Zucker

المصدر: BMJ Open, Vol 11, Iss 6 (2021)

مصطلحات موضوعية: Medicine

الوصف: Objective To characterise the long-term outcomes of patients with COVID-19 admitted to a large New York City medical centre at 3 and 6 months after hospitalisation and describe their healthcare usage, symptoms, morbidity and mortality.Design Retrospective cohort through manual chart review of the electronic medical record.Setting NewYork-Presbyterian/Columbia University Irving Medical Center, a quaternary care academic medical centre in New York City.Participants The first 1190 consecutive patients with symptoms of COVID-19 who presented to the hospital for care between 1 March and 8 April 2020 and tested positive for SARS-CoV-2 on reverse transcriptase PCR assay.Main outcome measures Type and frequency of follow-up encounters, self-reported symptoms, morbidity and mortality at 3 and 6 months after presentation, respectively; patient disposition information prior to admission, at discharge, and at 3 and 6 months after hospital presentation.Results Of the 1190 reviewed patients, 929 survived their initial hospitalisation and 261 died. Among survivors, 570 had follow-up encounters (488 at 3 months and 364 at 6 months). An additional 33 patients died in the follow-up period. In the first 3 months after admission, most encounters were telehealth visits (59%). Cardiopulmonary symptoms (35.7% and 28%), especially dyspnoea (22.1% and 15.9%), were the most common reported symptoms at 3-month and 6-month encounters, respectively. Additionally, a large number of patients reported generalised (26.4%) or neuropsychiatric (24.2%) symptoms 6 months after hospitalisation. Patients with severe COVID-19 were more likely to have reduced mobility, reduced independence or a new dialysis requirement in the 6 months after hospitalisation.Conclusions Patients hospitalised with SARS-CoV-2 infection reported persistent symptoms up to 6 months after diagnosis. These results highlight the long-term morbidity of COVID-19 and its burden on patients and healthcare resources.

وصف الملف: electronic resource

العلاقة: https://bmjopen.bmj.com/content/11/6/e049488.fullTest; https://doaj.org/toc/2044-6055Test

الوصول الحر: https://doaj.org/article/7571f8dd0bfb4ce39be803f501dd3b4aTest

المؤلفون: A. J. Dixon, H. K. Steinman, A. Kyrgidis, H. Smith, M. Sladden, C. Zouboulis, G. Argenziano, Z. Apalla, A. Lallas, C. Longo, A. Nirenberg, C. Popescu, T. Tzellos, L. Cleaver, C. Zachary, S. Anderson, J. M. Thomas

المساهمون: Dixon, A., Steinman, H. K., Kyrgidis, A., Smith, H., Sladden, M., Zouboulis, C., Argenziano, G., Apalla, Z., Lallas, A., Longo, C., Nirenberg, A., Popescu, C., Tzellos, T., Cleaver, L., Zachary, C., Anderson, S., Thomas, J. M.

المصدر: Journal of the European Academy of Dermatology and Venereology.

مصطلحات موضوعية: Infectious Diseases, Dermatology

الوصف: Background: Breslow thickness, patient age and ulceration are the three most valuable clinical and pathological predictors of melanoma survival. A readily available reliable online tool that accurately considers these and other predictors could be valuable for clinicians managing melanoma patients. Objective: To compare online melanoma survival prediction tools that request user input on clinical and pathological features. Methods: Search engines were used to identify available predictive nomograms. For each, clinical and pathological predictors were compared. Results: Three tools were identified. The American Joint Committee on Cancer tool inappropriately rated thin tumours as higher risk than intermediate tumours. The University of Louisville tool was found to have six shortcomings: a requirement for sentinel node biopsy, unavailable input of thin melanoma or patients over 70 years of age and less reliable hazard ratio calculations for age, ulceration and tumour thickness. The LifeMath.net tool was found to appropriately consider tumour thickness, ulceration, age, sex, site and tumour subtype in predicting survival. Limitations: The authors did not have access to the base data used to compile various prediction tools. Conclusion: The LifeMath.net prediction tool is the most reliable for clinicians in counselling patients with newly diagnosed primary cutaneous melanoma regarding their survival prospects.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3208ad3e3b4879de1b824f3006eb2085Test
https://doi.org/10.1111/jdv.19219Test

المؤلفون: C Patruno, M Napolitano, G Argenziano, K Peris, M Ortoncelli, G Girolomoni, A Offidani, S M Ferrucci, G F Amoruso, M Rossi, L Stingeni, G Malara, T Grieco, C Foti, M Gattoni, C Loi, M Iannone, M Talamonti, G Stinco, F Rongioletti, P D Pigatto, A Cristaudo, E Nettis, M Corazza, F Guarneri, P Amerio, M Esposito, A Belloni Fortina, C Potenza, G Fabbrocini, DADE - Dupilumab for Atopic Dermatitis of the Elderly study group

المساهمون: Patruno, C, Napolitano, M, Argenziano, G, Peris, K, Ortoncelli, M, Girolomoni, G, Offidani, A, M Ferrucci, S, F Amoruso, G, Rossi, M, Stingeni, L, Malara, G, Grieco, T, Foti, C, Gattoni, M, Loi, C, Iannone, M, Talamonti, M, Stinco, G, Rongioletti, F, D Pigatto, P, Cristaudo, A, Nettis, E, Corazza, M, Guarneri, F, Amerio, P, Esposito, M, Belloni Fortina, A, Potenza, C, Fabbrocini, G, Dupilumab for Atopic Dermatitis of the Elderly study group, Dade

مصطلحات موضوعية: atopic dermatiti, dupilumab, elderly

الوصف: Background: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33332697; info:eu-repo/semantics/altIdentifier/wos/WOS:000608704000001; firstpage:1; lastpage:7; numberofpages:7; journal:JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY; http://hdl.handle.net/11573/1475104Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85099666117

الإتاحة: https://doi.org/10.1111/jdv.17094Test
http://hdl.handle.net/11573/1475104Test

المؤلفون: Pavan S. Upadhyayula, Eleonora F. Spinazzi, Michael G. Argenziano, Peter Canoll, Jeffrey N. Bruce

المصدر: Pharmaceutics; Volume 13; Issue 1; Pages: 39

مصطلحات موضوعية: convection enhanced delivery, glioma, glioblastoma, topotecan

الوصف: A key limitation to glioma treatment involves the blood brain barrier (BBB). Convection enhanced delivery (CED) is a technique that uses a catheter placed directly into the brain parenchyma to infuse treatments using a pressure gradient. In this manuscript, we describe the physical principles behind CED along with the common pitfalls and methods for optimizing convection. Finally, we highlight our institutional experience using topotecan CED for the treatment of malignant glioma.

وصف الملف: application/pdf

العلاقة: Drug Delivery and Controlled Release; https://dx.doi.org/10.3390/pharmaceutics13010039Test

الإتاحة: https://doi.org/10.3390/pharmaceutics13010039Test

المؤلفون: E. Grande, H. Glen, J. Aller, G. Argenziano, M. J. Lamas, P. Ruszniewski, J. L. Zamorano, K. Edmonds, S. Sarker, M. Staehler, J. Larkin

المصدر: Onkourologiâ, Vol 16, Iss 4, Pp 61-81 (2020)

مصطلحات موضوعية: коррекция дозы, эверолимус, ленватиниб, оптимизация, почечно-клеточный рак, терапия, безопасность, Medicine

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1411Test; https://doaj.org/toc/1726-9776Test; https://doaj.org/toc/1996-1812Test; https://doaj.org/article/3a78f143180242ec99cc7653ed4beabaTest

الإتاحة: https://doi.org/10.17650/1726-9776-2020-16-4-61-81Test
https://doaj.org/article/3a78f143180242ec99cc7653ed4beabaTest